1375 related articles for article (PubMed ID: 27207799)
1. Toxicities of chimeric antigen receptor T cells: recognition and management.
Brudno JN; Kochenderfer JN
Blood; 2016 Jun; 127(26):3321-30. PubMed ID: 27207799
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
Shank BR; Do B; Sevin A; Chen SE; Neelapu SS; Horowitz SB
Pharmacotherapy; 2017 Mar; 37(3):334-345. PubMed ID: 28079265
[TBL] [Abstract][Full Text] [Related]
4. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
6. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
7. Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome.
Banerjee R; Fakhri B; Shah N
Leuk Lymphoma; 2021 Nov; 62(11):2600-2611. PubMed ID: 34151714
[TBL] [Abstract][Full Text] [Related]
8. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
9. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
10. Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.
Bailey SR; Vatsa S; Larson RC; Bouffard AA; Scarfò I; Kann MC; Berger TR; Leick MB; Wehrli M; Schmidts A; Silva H; Lindell KA; Demato A; Gallagher KME; Frigault MJ; Maus MV
Blood Cancer Discov; 2022 Mar; 3(2):136-153. PubMed ID: 35015685
[TBL] [Abstract][Full Text] [Related]
11. Toxicities associated with adoptive cellular therapies.
Hansen DK; Dam M; Faramand RG
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101287. PubMed ID: 34625233
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
[TBL] [Abstract][Full Text] [Related]
13. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
14. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
[TBL] [Abstract][Full Text] [Related]
15. Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team.
Martino M; Macheda S; Aguglia U; Arcudi L; Pucci G; Martino B; Altomonte M; Rossetti AM; Cusumano G; Russo L; Imbalzano L; Stelitano C; Alati C; Germano' J; Labate D; Amalfi V; Florenzano MT; Morabito A; Borzumati V; Dattola V; Gattuso C; Moschella A; Quattrone D; Curmaci F; Franzutti C; Scappatura G; Rao CM; Loddo V; Pontari A; Pellicano' M; Surace R; Sanguedolce C; Naso V; Ferreri A; Irrera G; Console G; Moscato T; Loteta B; Canale FA; Trimarchi A; Monteleone R; Al Sayyad S; Cirrone F; Bruno B
Expert Opin Biol Ther; 2022 Mar; 22(3):407-421. PubMed ID: 34463175
[TBL] [Abstract][Full Text] [Related]
16. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
Read JA; Rouce RH; Mo F; Mamonkin M; King KY
Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
19. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.
Frey N; Porter D
Biol Blood Marrow Transplant; 2019 Apr; 25(4):e123-e127. PubMed ID: 30586620
[TBL] [Abstract][Full Text] [Related]
20. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
Park JH; Geyer MB; Brentjens RJ
Blood; 2016 Jun; 127(26):3312-20. PubMed ID: 27207800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
